title: Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply.
authors.affiliation: Inflammatory Bowel Disease Centre, Yokkaichi Hazu Medical Centre, Yokkaichi, Mie, Japan. nao-taka@sannet.ne.jp.
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.affiliation: Inflammatory Bowel Disease Centre, Yokkaichi Hazu Medical Centre, Yokkaichi, Mie, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Shimoyama
authors.affiliation: Inflammatory Bowel Disease Centre, Yokkaichi Hazu Medical Centre, Yokkaichi, Mie, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Umegae
authors.affiliation: Inflammatory Bowel Disease Centre, Yokkaichi Hazu Medical Centre, Yokkaichi, Mie, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016559:Tacrolimus